Are ER+PR+ and ER+PR- breast tumors genetically different? A CGH array study

Cancer Genetics

Volumn 205, Issue 4, 2012, Pages 138-146

  Carracedo, Alma ^a,b   Salido, Marta ^a   Corominas, Josep M ^a   Rojo, Federico ^a   Ferreira, Bibiana I ^c   Suela, Javier ^c   Tusquets, Ignasi ^a   Corzo, Cristina ^d   Segura, Marcel ^a   Espinet, Blanca ^a   Cigudosa, Juan C ^c   Arumi, Montserrat ^a   Albanell, Joan ^a   Serrano, Sergi ^a   Solé, Francesc ^a,b  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Structural Biology and Biocomputing Programme   (Spain)

^d Del Mar University   (Spain)

Author keywords

Breast; Cancer; CGH array; ER; PR

Indexed keywords

DNA; ESTROGEN RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE RECEPTOR; PROTEIN KINASE B;

AGED; ANGIOGENESIS; APOPTOSIS; ARTICLE; BREAST CANCER; CELL SPREADING; CHROMOSOME 14; CHROMOSOME 17; CHROMOSOME 20; CHROMOSOME 21; CHROMOSOME 22; CHROMOSOME 3; CHROMOSOME 8; CHROMOSOME 9; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DNA ISOLATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MAP3K3 GENE; MITOSIS; PRIORITY JOURNAL; RPS6KB1 GENE; TISSUE MICROARRAY; TUMOR SUPPRESSOR GENE; ZNF217 GENE; BIOSYNTHESIS; BREAST TUMOR; COPY NUMBER VARIATION; DNA MICROARRAY; FEMALE; GENE DELETION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PATHOLOGY;

AGED; APOPTOSIS; BREAST NEOPLASMS; DNA COPY NUMBER VARIATIONS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SEQUENCE DELETION;

EID: 84862731808     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2012.01.001     Document Type: Article

References (48)

1. Chen G.G., Zeng Q., Tse G.M. Estrogen and its receptors in cancer. Med Res Rev 2008, 28:954-974.
2. Cui X., Schiff R., Arpino G., et al. Biology of progesterone loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 2005, 23:7721-7735.
3. McGuire W. Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol 1978, 5:428-433.
4. Osborne C.K. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998, 339:1609-1618.
5. Bardou V.J., Arpino G., Elledge R.M., et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003, 21:1073-1079.
6. Dowsett M. Analysis of time to recurrence in the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial according to estrogen receptor and progesterone receptor status. Breast Cancer Res Treat 2003, S2:S7. On behalf of the ATAC trialists group, [abstract].
7. Horwitz K.B., McGuire W.L. Estrogen control of progesterone receptor in human breast cancer. J Biol Chem 1978, 253:2223-2228.
8. Bloom N.D., Tobin E.H., Shcreibman B., et al. The role of progesterone receptors in the management of advanced breast cancer. Cancer 1980, 45:2992-2997.
9. Tomlinson I.P., Nicolai H., Solomon E., et al. The frequency and mechanism of loss of heterozygosity on chromosome 11q in breast cancer. J Pathol 1996, 180:38-43.
10. Winqvist R., Hampton G.M., Mannermaa A., et al. Loss of heterozygosity for chromosome 11 in primary human breast tumors is associated with poor survival after metastasis. Cancer Res 1995, 55:2660-2664.
11. Lapidus R.G., Ferguson A.T., Ottaviano Y.L., et al. Methylation of estrogen and progesterone receptor gene 5' CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin Cancer Res 1996, 2:805-810.
12. Arpino G., Weiss H., Lee V.A., et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer; association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 2005, 97:1254-1261.
13. Letessier A., Sircoulomb F., Ginestier C. Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12 and 20q13 amplifications in breast cancers. BMC Cancer 2006, 6:245-256.
14. Chin K., DeVries S., Fridlyand J., et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006, 10:529-541.
15. Creighton C., Osborne K., Van de Viver M. Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat 2009, 114:287-299.
16. Eilers P.H., de Menezes R.X. Quantile smoothing of array CGH data. Bioinformatics 2005, 21:1146-1153.
17. Kononen J., Bubendorf L., Kallioniemi A., et al. Tissue microarrays for high throughput molecular profiling of tumor specimens. Nat Med 1998, 4:844-847.
18. Salido M., Tusquets I., Corominas J.M., et al. Polysomy of chromosome 17 in breast cancer showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry. Breast Cancer Res 2005, 7:R267-R273.
19. Hennessy B.T., Smith D.L., Ram P.T., et al. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005, 4:988-1004.
20. Lambros M.B., Natrajan R., Geyer F.C., et al. PPM1D gene amplification and overexpression in breast cancer: QRT-PCR and chromogenic in situ hybridization study. Mod Pathol 2010, 23:1344-1345.
21. Guraraj A.E., Holm C., Landberg G., et al. Breast cancer-amplified sequence 3, a target of metastasis-associated protein 1, contributes to tamoxifen resistance in premenopausal patients with breast cancer. Cell Cycle 2006, 5:1407-1410.
22. Samanta A.K., Huang H.J., Bast R.C., et al. Overexpression of MEKK3 confers resistance to apoptosis through activation of NFkB. J Biol Chem 2004, 9:7576-7583.
23. Nessling M., Richter K., Schawaenen C., et al. Candidate genes in breast cancer revealed by microarray-based comparative genomic hybridization of archived tissue. Cancer Res 2005, 65:439-447.
24. Haverty P.M., Fridlyand J., Li L., et al. High-resolution genomic and expression analyses of copy number alterations in breast tumors. Genes Chromosomes Cancer 2008, 47:530-542.
25. Fang M., Toher J., Morgan M., et al. Genomic differences between estrogen receptor (ER)-positive and ER-negative human breast carcinoma identified by single nucleotide polymorphism array comparative genome hybridization analysis. Cancer 2011, 117:2024-2034.
26. Hesson L.B., Cooper W.N., Latif F. Evaluation of the 3p21.2 tumour-suppressor gene cluster. Oncogene 2007, 26:7283-7301.
27. Dammann R., Yang G., Pfeifer G.P. Hypermethylation of the CpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res 2001, 61:3105-3109.
28. Yang Q., Yoshimura G., Mori I., et al. Chromosome 3p and breast cancer. J Hum Genet 2002, 47:453-459.
29. Yang Q., Nakamura M., Nakamura Y., et al. Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer. Clin Cancer Res 2002, 8:3890-3893.
30. Martínez A., Walker R.A., Shaw J.A., et al. Chromosome 3p allele loss in early invasive breast cancer: detailed mapping and association with clinicopathological features. Mol Pathol 2001, 53:300-306.
31. Guler G., Huebner K., Himmetoglu C., et al. Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2gamma expression levels correlate with basal phenotype in breast cancer. Cancer 2005, 15:899-908.
32. Rocco J.W., Sidransky D. P16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res 2001, 264:42-55.
33. Fahraeus R., Lane D.P. The p16(INK4a) tumour suppressor protein inhibits alphavbeta3 integrin-mediated cell spreading on vitronectin by blocking PKC-dependent localization of alphavbeta3 to focal contacts. EMBO J 1999, 18:2106-2118.
34. Harada H., Nakagawa K., Iwata S., et al. Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas. Cancer Res 1999, 59:3783-3789.
35. Reynolds P.A., Sigaroudinia M., Zardo G. Tumor suppressor p16INK4A regulates polycomb-mediated DNA hypermethylation in human mammary epithelial cells. J Biol Chem 2006, 25:24790-247802.
36. Royds J.A., Lacopetta B. p53 and disease: when the guardian angel fails. Cell Death Differ 2006, 13:1017-1026.
37. Zhan Y.J., Kurtycz Q.Z., Vacano G., et al. Methylation-mediated downregulation of the B-cell translocation gene 3 (BTG3) in breast cancer cells. Gene Expression 2008, 14:173-182.
38. Ou Y.H., Chung P.H., Hsu F.F., et al. The candidate tumor suppressor BTG3 is a transcriptional target of p53 that inhibits E2F1. EMBO J 2007, 26:3968-3980.
39. Huang G., Krig S., Kowbel D., et al. ZNF217 suppresses cell death associated with chemotherapy and telomere dysfunction. Hum Mol Gen 2005, 14:3219-3225.
40. Quinlan K., Verger A., Yaswen P., et al. Amplification of zinc finger gene 217 (ZNF217) and cancer: when good fingers go bad. Biochim Biophys Acta 2007, 1775:333-340.
41. Collins C., Stanislav V., Kowbel D., et al. Comprehensive genome sequence analysis of a breast cancer amplicon. Genome Res 2001, 11:1034-1042.
42. Heinonen H., Nieminen A., Saarela M., et al. Deciphering downstream gene targets of PI3K/Mtor/p70S6K pathway in breast cancer. BMC Genomics 2008, 9:348.
43. Barlünd M., Monni O., Kononen J., et al. Multiple genes at 17q23 undergo amplification and overexpression in breast cancer. Cancer Res 2000, 60:5340-5344.
44. Monni O., Bärlund M., Mousses S., et al. Comprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancer. Proc Natl Acad Sci USA 2005, 98:5711-5716.
45. Barlünd M., Forozan F., Kononen J., et al. Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J Natl Cancer Inst 2000, 92:1252-1259.
46. Erson A.E., Niell B.L., DeMers S.K., et al. Overexpressed genes/ESTs and characterization of distinct amplicons on 17q23 in breast cancer cells. Neoplasia 2001, 3:521-526.
47. Wu G., Sinclair C., Hinson S., et al. Structural analysis of the 17q22-23 amplicon identifies several independent targets of amplification in breast cancer cell lines and tumors. Cancer Res 2001, 61:4951-4955.
48. Pärssinen J., Kuukasjärvi T., Karhu R., et al. High-level amplification of 17q23 leads to coordinated overexpression of multiple adjacent genes in breast cancer. Br J Cancer 2007, 96:1258-1264.